Issue of Equity

Synexus Clinical Research PLC
03 December 2007



For release on 3 December 2007


SYNEXUS CLINICAL RESEARCH PLC (the "Company")


Issue of Equity

The Company announces that at a board meeting held on 28 November 2007 it
conditionally agreed to allot 250,000 ordinary shares of 10p each in the Company
("Shares") to Alan Boyce and 159,178 Shares to Paul McCluskey following the
exercise of their options becoming effective under the Company's Enterprise
Management Incentive and Unapproved Share Scheme (in aggregate the "New 
Shares").  Mr Boyce, the Company's Chief Operating Officer, exercised his 
options at a price of 52.5p per Share and Mr McCluskey, the Company's Chief 
Financial Officer, exercised his options at a price of 62.5p per Share.  The 
condition to the allotments was met by the offer by Sigma Acquisitions Limited 
for the entire issued and to be issued share capital of the Company 
(the "Offer") being declared unconditional as to acceptances on 30 November 
2007.

Application has been made for admission of the New Shares to trading on the AIM
market of the London Stock Exchange on Wednesday 5 December 2007.

The enlarged issued share capital of the Company following this issue and
allotment consists of 23,563,350 Shares.


ENDS

                      This information is provided by RNS
            The company news service from the London Stock Exchange